Combined in-vivo and in-vitro capabilities for faster efficacy assessment
Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
Archives for December 23, 2019
3M set to sell biopharma-focused CDMO for $650m
3M agrees to sell drug delivery contract service unit to investment group Altaris Capital Partners.